1. Combining Immunotherapy and Chemotherapy in NSCLC

3. Content Outline

4. Chemotherapy Promotes Immunogenic Responses Through Multiple Mechanisms

5. Chemotherapy Promotes Immunogenic Responses Through Multiple Mechanisms

6. Combinations in NSCLC Updated Approvals in 2019

7. Anti-PD-1 Monotherapy Long-Term Follow-Up Continues to Impress

8. Pooled Long-Term Analysis of CheckMate-017/-057*

9. Recent Updates to KEYNOTE-189

10. KEYNOTE-021 Cohort G Longer-Term Follow-Up Continues to Favor Pembrolizumab

11. IMpower150 Identifies Key Subgroups That May Benefit From Quadruplet Therapy

12. Is Liver Metastasis a Biomarker for Selection of Combination Regimens?

13. Optimizing Treatment Selection for PD-L1-High NSCLC Single Agent or Combo?

14. IMpower132 Confirming Chemo-Immunotherapy Combo Efficacy

15. Immune Checkpoint Combination for Squamous-Cell Disease IMpower131

16. CheckMate-227 Focusing on Chemo-Immunotherapy in PD-L1-Negative NSCLC

17. Tumor Mutational Burden as a Biomarker of Immunotherapy

18. Exploratory MYSTIC Findings Demonstrating an Effect of High TMB on Immune Priming

19. Patient Case

20. Considerations for Optimal First-Line Treatment Selection, High PD-L1 and TMB

21. Optimal Treatment Selection for PD-L1-Low (20%) or Negative (<1%) NSCLC New Considerations

22. Following ESMO Guidelines for Non Squamous NSCLC First-Line Treatment

23. Important Ongoing Studies in Lung Cancer

24. The INSIGNA Trial Defining an Optimal Sequence for Advanced NSCLC

25. Keys to Managing Immunologic Adverse Events

26. Is Re-Challenge With Immunotherapy Feasible After a Serious Adverse Event?

27. Key Takeaways

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)